| dbo:abstract
|
- The Bracco Group is an Italian multinational active in the healthcare sector with more than 3,300 employees worldwide, which operates in a variety of business areas.
* Diagnostic imaging, with products for X-ray imaging, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine.
* Contrast-agent injection systems and advanced medical devices.
* Prescription and over-the-counter pharmaceuticals, supplements, medical and cosmetic devices developed and distributed in Italy.
* Healthcare, prevention, diagnosis and rehabilitation services through the CDI - Centro Diagnostico Italiano. Bracco has consolidated revenues of more than 1.1 billion euro, of which 75% from international sales. The Group is present in 100 countries and invests approximately 10% of its core diagnostic imaging revenues in research and innovation.In Italy Bracco is also a brand associated with a number of historic pharmaceutical products such as Cebion, Xamamina, Euclorina, the Alfa eye-drops line and the Friliver range of sport supplements. The Group Chairman and Chief Executive Officer is Diana Bracco. A chemistry graduate from the University of Pavia, Diana Bracco is also Chairman of Expo 2015 Spa, General Section Commissioner for the Italy Pavilion at Expo and Confindustria Vice President for Research & Innovation. Decorated as a Cavaliere del Lavoro, she was President of Assolombarda and, before that, Chairman of Federchimica. In February 2001 she received an Honorary Doctor of Pharmacy degree from University of Pavia.On January 12, 2015, Diana Bracco was "prosecuted on charges of tax evasion and embezzlement, crimes allegedly committed as chairman of the board of the pharmaceutical group Bracco Spa." In October 2016, she was given a two year suspended sentence for tax fraud and embezzlement. As of 2020, the group has a consolidated turnover of approximately 1.4 billion euros, of which 89% on foreign markets. It is present in 100 countries with 3,587 employees. The Bracco group has 1,800 patents, 7 research and development centers and 9 factories worldwide. (en)
- Bracco ist ein italienisches Pharma- und Diagnostikunternehmen. Die Tochtergesellschaft Bracco Imaging (früher Dibra) ist weltweit führend in der Bildgebung. Bracco wurde 1927 als Italmerck gegründet. 1934 wurde die Produktion von Ascorbinsäure (Cebion) aufgenommen. Nach dem Zweiten Weltkrieg wurde das Sulfonamid Sulfadimidin (Diazil) produziert. In den 1970ern wurde das Röntgen-Kontrastmittel Iopamidol entwickelt und 1981 auf den Markt gebracht. 1994 wurde Squibb Diagnostics von BMS übernommen. 2001 wurde Schwefelhexafluorid als (SonoVue) Ultraschall-Kontrastmittel etabliert. Bei Pyrazinamid ist Bracco der größte Produzent weltweit. (de)
- Il Gruppo Bracco è una multinazionale italiana del settore chimico e farmaceutico fondata nel 1927 da . Negli anni ’70 ha sviluppato la molecola di iopamidolo, mezzo di contrasto non-ionico pronto all'uso impiegato nell'imaging biomedico diventando nel tempo uno dei maggiori leader mondiali nei mezzi di contrasto per la diagnostica per immagini. Al 2020, il gruppo ha un fatturato consolidato di circa 1,4 miliardi di euro di cui l'89% sui mercati esteri. È presente in 100 paesi con 3.587 dipendenti. Il gruppo Bracco conta 1.800 brevetti, 7 centri di ricerca e sviluppo e 9 stabilimenti a livello mondiale. (it)
|
| dbo:foundingYear
| |
| dbo:numberOfEmployees
|
- 3400 (xsd:nonNegativeInteger)
|
| dbo:thumbnail
| |
| dbo:type
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 11491 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:areaServed
| |
| dbp:foundation
| |
| dbp:founder
| |
| dbp:industry
|
- Chemical, pharmaceutical (en)
|
| dbp:keyPeople
| |
| dbp:locationCountry
| |
| dbp:logo
| |
| dbp:name
| |
| dbp:numEmployees
| |
| dbp:products
|
- contrast agents, injectors, medical devices, pharma (en)
|
| dbp:revenue
|
- (en)
- eur 1.3 billion (en)
|
| dbp:type
| |
| dbp:website
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Bracco ist ein italienisches Pharma- und Diagnostikunternehmen. Die Tochtergesellschaft Bracco Imaging (früher Dibra) ist weltweit führend in der Bildgebung. Bracco wurde 1927 als Italmerck gegründet. 1934 wurde die Produktion von Ascorbinsäure (Cebion) aufgenommen. Nach dem Zweiten Weltkrieg wurde das Sulfonamid Sulfadimidin (Diazil) produziert. In den 1970ern wurde das Röntgen-Kontrastmittel Iopamidol entwickelt und 1981 auf den Markt gebracht. 1994 wurde Squibb Diagnostics von BMS übernommen. 2001 wurde Schwefelhexafluorid als (SonoVue) Ultraschall-Kontrastmittel etabliert. (de)
- The Bracco Group is an Italian multinational active in the healthcare sector with more than 3,300 employees worldwide, which operates in a variety of business areas.
* Diagnostic imaging, with products for X-ray imaging, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine.
* Contrast-agent injection systems and advanced medical devices.
* Prescription and over-the-counter pharmaceuticals, supplements, medical and cosmetic devices developed and distributed in Italy.
* Healthcare, prevention, diagnosis and rehabilitation services through the CDI - Centro Diagnostico Italiano. (en)
- Il Gruppo Bracco è una multinazionale italiana del settore chimico e farmaceutico fondata nel 1927 da . Negli anni ’70 ha sviluppato la molecola di iopamidolo, mezzo di contrasto non-ionico pronto all'uso impiegato nell'imaging biomedico diventando nel tempo uno dei maggiori leader mondiali nei mezzi di contrasto per la diagnostica per immagini. (it)
|
| rdfs:label
|
- Bracco (Unternehmen) (de)
- Bracco (company) (en)
- Bracco (azienda) (it)
|
| owl:sameAs
| |
| skos:closeMatch
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:homepage
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageDisambiguates
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
